Patient and Provider Initiated Survivorship Care Planning

Background/Rationale: In a 2005 report 'From Cancer Patient to Cancer Survivor: Lost in
Transition', the Institute of Medicine recommended that cancer patients completing treatment
receive a summary of the care received and a plan outlining follow-up care needs. Taken
together these materials are referred to as a 'Survivorship Care Plan', or SCPs. Based on
this recommendation from the IOM, a number of organizations developed survivorship care plan
templates. Two of these templates, 'Survivorship Care Plan Builder' and 'My Care Plan,' were
developed by Journey Forward, a collaboration among the National Coalition for Cancer
Survivorship, UCLA Cancer Survivorship Center, Oncology Nursing Society, WellPoint, Inc.,
and Genentech (http://journeyforward.org/). These tools are available free of charge to
those wishing to use them. As the time and effort required to complete SCP documents have
been found to be barriers to implementation, this study aims to explore the use of these two
tools.

Research Questions:

1. What processes are undertaken to implement survivorship care planning?

- How do these processes differ between the patient-initiated My Care Plan and
provider-initiated Survivorship Care Plan Builder?

2. What is the feasibility of implementing survivorship care planning?

- Does the feasibility differ between the patient-initiated My Care Plan and
provider-initiated Survivorship Care Plan Builder?

3. What is the value of survivorship care planning to both patients and providers?

- Does the value differ between the patient-initiated My Care Plan and
provider-initiated Survivorship Care Plan Builder?

Study Design: This is a pilot randomized study. Cancer patients completing acute treatment
with a participating provider will be randomized to either the patient-initiated My Care
Plan tool or provider-initiated Survivorship Care Plan Builder. The investigators will
describe and compare how each tool is implemented in practice, the feasibility of completing
each tool, and the value of the tools to patients and providers. The study will use
quantitative and qualitative measures of implementation, feasibility, and value.

Inclusion Criteria:

1. Have you diagnosed with non-metastatic (i.e., stages I - III) cancer (non-melanoma
skin cancer)

2. Have you completed acute treatment with intent to cure within the past 2 months
(ongoing long-term maintenance therapy such as adjuvant hormonal therapy is allowed)

3. What clinician primarily managed your cancer treatment? (must be a participating
Sibley or Suburban clinician)

Exclusion Criteria:

1. Do you show any evidence of disease?